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Abstract 
Background: The knowledge of general practitioner(s) (GPs) regarding food allergy and anaphylaxis and practices in 
the prescription of epinephrine auto‑injector(s) (EAIs) among GPs has previously only been studied using question‑
naires and hypothetical cases. Therefore, there are currently no data as to whether or not GPs prescribe EAIs to high 
risk food‑allergic patients presenting to primary care practices. The aim of this study was therefore to describe and 
evaluate practice in EAI prescription by GPs to food‑allergic patients in The Netherlands.
Methods: Patients aged 12–23 years who consulted their GP for allergic symptoms were identified in a primary care 
database. Patients were classified as probably or unlikely to be food‑allergic. A risk factor assessment was done to 
identify probably food‑allergic patients at high risk for anaphylaxis to assess the need for an EAI.
Results: One hundred forty‑eight out of 1015 patients consulted their GP for allergic symptoms due to food. Eighty 
patients were excluded from analysis because of incomplete records. Thirty‑four patients were classified as probably 
food‑allergic. Twenty‑seven of them were considered high risk patients and candidates for an EAI. Importantly, only 10 
of them had actually been prescribed an EAI by their GP.
Conclusions: This study shows that high risk food‑allergic patients that visit their GPs are often not prescribed an EAI. 
Thus, previously identified low rates of EAI ownership may be partly due to GPs not prescribing this medication to 
patients for whom it would be appropriate to do so. These data suggest that there is a need for improvement of the 
quality of care for high risk food‑allergic patients in primary care.
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Background
General practitioners (GPs) play an important role in 
diagnosing and treating food-allergic patients. In The 
Netherlands, the GP is the gatekeeper of the Dutch 
health-care system controlling access to specialized med-
ical care.
Previous studies have shown that many high risk food-
allergic patients do not have an epinephrine auto-injector 
(EAI) and that GPs are not always knowledgeable about 
these patients [1–10]. These studies show that there is a 
lack of allergy knowledge in primary care, especially the 
recognition and treatment of anaphylaxis were problem-
atic and that national guidelines were often not followed.
Adolescents are the age-group with the highest risk for 
food allergy fatalities [11]. The fact that they often engage 
in risk-taking behaviors [12–14] resulting in reduced 
vigilance about food consumption or reluctance to carry 
their EAI may contribute to this outcome [13–16].
The knowledge of GPs regarding food allergy and ana-
phylaxis, and practices in the prescription of EAIs among 
GPs, has previously only been studied using question-
naires and hypothetical cases. Therefore, there are cur-
rently no data as to whether GPs actually do prescribe 
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EAIs to high risk food-allergic patients presenting to pri-
mary care practices. The aim of this study was therefore 
to describe and evaluate practice in EAI prescriptions by 
GPs to food-allergic patients in The Netherlands.
Methods
Study design
A retrospective analysis was performed on data from the 
electronic database of Registration Network Groningen 
(RNG). This general practice-based research network was 
established in 1989 and consists of patient registrations 
of three group practices based in the Northern part of 
The Netherlands. The RNG includes a dynamic popula-
tion with an average annual population of approximately 
30,000 patients.
Participating general practitioners use a structured 
medical record, in which all patient contacts are regis-
tered. This includes reason for encounter, medical diag-
nosis (according to the International Classification of 
Primary Care (ICPC), applied treatment including pre-
scriptions, using the Anatomical Therapeutic Chemical 
(ATC) codes, and referrals.
From the RNG database, of the target study popula-
tion (patients between 12 and 23 years old), a dataset was 
extracted with information about patients’ consultations 
for symptoms related to allergy and prescriptions of EAIs 
by GPs from 2001 to 2012. In this study, patients with 
allergic symptoms were identified using the ICPC-codes 
A12 (allergy), T04 (feeding problem of infant/child), and 
T05 (feeding problem of adult). The EAI prescription 
was defined as the ATC-group C01CA24 (epinephrine). 
The database included the following additional informa-
tion: date of birth, date of entry in the general practice 
database, GP code, type and number of patient contacts 
(ICPC codes), prescriptions (ATC codes) and ICPC 
codes associated with these medications, and (hospital) 
referrals.
Study population
The study population consisted of patients aged 
12–23  years who consulted their GP for allergic symp-
toms due to food from 2001 to 2012. Access to the 
patient’s medical history was a prerequisite. Patients were 
excluded from analyses if they did not have allergic symp-




Patients’ medical records were evaluated to identify 
patients who experienced allergic symptoms solely to 
food.
Patient age and gender, suspected food(s), allergic 
symptoms at time of allergic reaction (37 specific symp-
toms of the mouth, nose, eyes, skin, gastrointestinal tract, 
respiratory tract, cardiovascular tract), time of onset and 
duration of allergic symptoms, atopic co-morbidities 
(asthma, atopic dermatitis, rhinitis), possession of an 
EAI, and information about other diagnostic tests, and 
(hospital) referral(s) were determined.
Patients were classified as probably food-allergic when 
the patient’s medical record indicated that the patient 
reported allergic symptoms after eating one of the fol-
lowing foods: peanut, tree nuts, milk, egg, wheat, soy, 
sesame seed, fish, shell fish, and celery. The foods chosen 
as allergenic food were based on the EU directive on labe-
ling of pre-packaged products (EU Directive 2003/89/EC 
amending Directive 2000/13/EC) relevant in The Neth-
erlands, i.e. peanut, nuts, milk, egg, wheat, soy, sesame 
seed, fish, shell fish, and celery. In addition, in patients 
also reporting reactions to fruits and vegetables, these 
reactions were documented.
Symptoms of the mouth, nose, eyes, skin, gastrointes-
tinal tract, respiratory tract, or cardiovascular tract were 
considered allergic symptoms. The presence of only sub-
jective gastrointestinal symptoms without other symp-
toms was not classified as food allergy.
Risk factor assessment and EAI indications
To identify patients who are at high risk for anaphylaxis 
and to assess the need for an EAI a risk factor assess-
ment based on the guidelines of the European Academy 
of Allergy and Clinical Immunology (EAACI) was carried 
out for each patient who experienced allergic symptoms 
due to food [17].
Risk factors for an anaphylactic reaction were defined 
as a previously severe anaphylactic reaction to a food 
requiring emergency treatment or hospitalization as 
a result, asthma or asthmatic reactions to food, adoles-
cent or young adult age, systemic reaction to traces of 
the food allergen, and having a peanut or nut allergy [18]. 
When the first factor was present or when at least two of 
the other risk factors were present in the context of sus-
pected or proven food allergy, food-allergic patients were 
considered high risk patients, and candidates for an EAI. 
Allergy only to fruits or vegetables with these risk factors 
did not constitute an indication for an EAI. All doubtful 
cases concerning food allergy and the need for an EAI 
were discussed with an allergist (AEJD).
Referrals
Indications for referral of a patient to a specialist with 
specific expertise on allergology were defined as patients 
who experienced allergic symptoms in association with 
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food exposure and who need further testing for the 
objective diagnosis of food allergy, patients who experi-
enced a severe allergic reaction, and patients being pre-
scribed an EAI [17, 19, 20].
Statistics
Data entry and analyses were conducted using SPSS ver-
sion 20.0 (SPSS Inc. Chicago, IL, USA). For the statistical 
analysis descriptive methods were used.
Ethical approval
We received ethical permission to access the Registration 
Network Groningen from the Medical Ethical Review 





In total there were 11,514 patients aged 12–23 years iden-
tified in the RNG database. Of these 11,514 patients, 1314 
patients (11.4  %) consulted their GP for allergic symp-
toms from 2001 to 2012 (Fig.  1). In total 299 patients’ 
medical records were not accessible because they could 
not be digitally restored from the archives. Therefore, a 
total of 1015 patients were eligible for analysis.
In total 148 patients (14.6 %) out of 1015 patients con-
sulted their GP for allergic symptoms due to food. Of 
these 148 patients, 80 patients were classified as ‘patients 
with incomplete data’ because no allergic symptoms were 
recorded by GP in the patient’s medical records. Of the 
remaining 68 patients, half (n  =  34) were classified as 
probably food-allergic, and the other half as unlikely to 
be food-allergic.
Most patients classified as probably food-allergic 
reported symptoms from tree nuts (44.1 %), milk (32.4 %) 
and peanuts (23.5 %). Most patients classified as unlikely 
food-allergic reported symptoms from milk (26.5  %). 
Descriptive characteristics are shown in Table 1.
Risk factor assessment and EAI indications
Thirty-four patients (3.3  %) out of 1015 patients who 
consulted their GP for allergic symptoms between 2001 
and 2012 were prescribed an EAI. Twenty EAIs were 
prescribed to patients who consulted their GP for aller-
gic symptoms due to food. The other 14 EAIs were 
prescribed to five patients who consulted their GP for 
allergic symptoms due to insect stings, to one patient on 
recommendation by a pediatrician, and to eight patients 
of whom the reason of prescription was not clearly 
recorded in the patient’s medical records.
High risk patients and EAIs
Twenty-seven (79.4 %) out of the 34 patients classified as 
probably food-allergic were considered high risk patients, 
and therefore candidates for an EAI. Ten (37 %) of them 
had actually been prescribed an EAI.
Five out of the 27 high risk patients experienced a pre-
vious anaphylactic reaction to food. All of these patients 
were aged 12–17  years, had a peanut and/or tree nut 
allergy and had asthma. Two (40  %) of them had been 
prescribed an EAI. One patient’s medical record showed 
that instructions/demonstrations had been given about 
when and how to use an EAI.
Low risk patients and EAIs
Seven (20.6 %) out of the 34 patients classified as prob-
ably food-allergic were considered low risk patients, and 
therefore not considered candidates for an EAI. Two 
(28.5  %) of them were prescribed an EAI. One patient 
had a sesame seed allergy and the other patient a fruit 
allergy, and both patients reported having asthma.
Patients with incomplete data and EAIs
Eighty patients were excluded from analysis in this 
study because no allergic symptoms were recorded in 
the patients’ medical records. In the records of four of 
these patients, it was remarked that they presented to 
the primary care practice with anaphylactic symptoms 
after eating food possibly containing peanuts or tree 
nuts. According to the risk factor assessment used for 
this study these patients were also considered high risk 
patients and candidates for an EAI. Importantly, one of 
them had not been prescribed an EAI. Descriptive char-
acteristics are shown in Table 1.
The other 76 patients of which allergic symptoms were 
not recorded in their medical record, a risk assessment 
could not be made nor could the need of an EAI be 
assessed. In the records of five of these 76 patients, it was 
remarked that they had been prescribed an EAI. In total 
eight EAIs were prescribed to patients with incomplete 
data.
Referrals
Twelve patients (32.4  %) (ten high risk and two low 
risk patients) classified as probably food-allergic were 
referred to a dietician and/or to one or more specialist(s). 
Of the other 22 probably food-allergic patients who were 
not referred, six were prescribed an EAI and one patient 
experienced anaphylactic symptoms.
Seven patients (20.6 %) classified as unlikely to be food-
allergic were referred to a dietician and/or to one or more 
specialist(s).
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None of the patients with incomplete data who expe-
rienced anaphylactic symptoms were referred to a 
specialist.
Discussion
Although the knowledge of GPs regarding food allergy 
and anaphylaxis has previously been studied using 
target age group in RNG database
n=11.514
patients with allergic symptoms
n=1314
investigation of medical records
patients with allergic 
symptoms to food
n=148 (11.3%)**







































Fig. 1 Flow chart of study *Medical records were not accessible because they could not be digitally restored from the archives; **Percentages 
represent those of the previous step in the chart; ***EAI, epinephrine auto‑injector
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questionnaires and hypothetical cases, this study is the 
first to examine actual epinephrine auto-injector pre-
scription practices and the first to make use of data col-
lected by GPs themselves.
Food-allergic patients aged 12–23  years at high risk 
for anaphylaxis who consult their GPs are often not pre-
scribed an EAI by the GP. Twenty-seven (79.4 %) out of 
the 34 patients classified as probably food-allergic were 
considered high risk patients, and therefore candidates 
for an EAI. Only ten (37  %) of them had actually been 
prescribed an EAI. In addition, five (18.5  %) out of the 
27 high risk patients experienced a previous anaphy-
lactic reaction to food. All of these patients were aged 
12–17  years, had a peanut and/or tree nut allergy and 
had asthma, and only two of them had been prescribed 
an EAI. This shows that previously identified low rates of 
Table 1 Descriptive characteristics of study population
EAI epinephrine auto‑injector
a Not documented in all patient’s medical records
b Unknown due to incomplete data, however, 4 patients had had presented to their GP with an anaphylactic reaction according to the information in the medical 
record. All of them had a peanut or nut allergy, and only 3 of them had been prescribed an EAI
Probably food-allergic Unlikely food-allergic Patients with incomplete data
Number participants, n (%) 34 (50) 34 (50) 80
Sex adolescent, boys/girls n (%) 17/17 (50/50) 13/21 (38/62) 43/37
Type of food allergies, n (%)
 Peanut 8 (23) 4 (12) 13 (16)
 Tree nuts 15 (44) 4 (12) 12 (15)
 Cow’s milk 11 (32) 9 (27) 38 (48)
 Egg 2 (6) 2 (6) 1 (1)
 Wheat 1 (6) – 0
 Soy – – 1 (1)
 Sesame seed 1 (3) – 0
 Fish – 2 (6) 1(1)
 Shell fish – 1 (3) 1 (1)
 Celery – 1 (3) 1 (1)
 Fruit – 8 (24) 15 (19)
 Vegetables – 2 (6) 2 (3)
 Other – 7(21) 3 (4)
Tests used to diagnose food allergy, n (%)
 Food‑specific IgE levels (RAST) 14 (59) 14 (59) 20 (25)
 Open food challenge 9 (27) 7 (21) 9 (11)
 Skin prick test 2 (6) – 1 (1)
Referral to, total n (%) 11 (32) 7 (21) 9 (11)
 (Pediatric) allergologist 2 (6) 1 (3) –
 Dermatologist – 1 (3) 1 (1)
 Pediatrician 2 (6) 2 (6) 1 (1)
 Internist 4 (12) 3 (9) 1 (1)
 Dietician 2 (6) 4 (12) 5 (6)
High risk patient, n (%) 27 (79) – 4 (5)b
Experienced anaphylaxis, n (%) 5 (15) – 4 (5)
Risk factors, n (%)
 Asthma or asthmatic reactions to food 10 (29) 3 (9) 9 (11)
 Adolescent or young adult age 21 (62) 24 (71) 70 (88)
 Systemic reaction to traces of the food allergena 6 (18) 1 (3) –
 Having peanut or nut allergy 23(68) 8 (24) 25 (32)
Prescribed an EAI, yes/no n (%) 8 (10)
 High risk patient 10/17 (29/71) – 1 (1)
 Low risk patient 2/8 (6/24) – 7 (9)
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EAI ownership may be partly due to GPs not prescribing 
this medication to patients for whom it would be appro-
priate to do so [1, 8–10, 21].
The clinical history is a key part of the diagnostic work-
up of suspected food allergy [17, 18]. Although the food 
allergy guidelines of the Dutch College of General Prac-
titioners (NHG) [20] recommends asking the patient 
about the symptoms and how long these occurred after 
ingestion, this study shows that many patients’ medi-
cal records were lacking this important information. 
This under-documentation might be due to the patients 
(or their parents) not clearly remembering or reporting 
their symptoms. Also, the limited time available to the 
GP to record the patient’s symptoms during a consulta-
tion might play a role. Finally, knowledge and/or practice 
behavior gaps in GPs might contribute, as is suggested by 
other studies [4–6, 9, 22].
Primary care guidelines in The Netherlands, the NHG 
guidelines [20], recommend that an EAI should only be 
prescribed after a previous case of anaphylaxis. Signifi-
cantly, risk factors for a life-threatening food induced ana-
phylactic reaction are mentioned, but are not put forward 
as an reason to prescribe an EAI in the absence of a pre-
vious anaphylactic reaction. Although it may therefore be 
argued that GPs are simply following their own guidelines, 
this does not seem to explain the lack of EAI prescription 
in 3 out of 5 high risk patients who had experienced prior 
anaphylaxis as well as 3 out of 4 patients presenting with 
anaphylaxis to their GP. The latter situation is in agree-
ment with previous studies of anaphylaxis management 
in emergency rooms, where patients presenting with ana-
phylaxis are not always prescribed an EAI or referred to 
appropriate specialist care allergy [17, 18].
The need for improved EAI training has been a recur-
ring theme in the literature on anaphylaxis [8, 11, 13, 23, 
24]. Anaphylaxis usually occurs in the community, there-
fore, all food-allergic patients and their parents (and other 
caregivers) should be provided with educational resources 
and training should cover avoidance strategies, recognition 
of symptoms, and when and how to administer an EAI. It 
was mentioned in one patient’s medical record that EAI 
instructions/demonstrations had been given. The NHG 
guidelines recommend giving clear instructions about the 
use of an EAI. It may thus be possible that GPs did give 
clear instructions about when and how to use an EAI, but 
that this was not documented. The general practices did 
not have demonstration material and trainer EAIs on hand. 
We found that GPs feel that giving instructions about how 
to use an EAI is the responsibility of the pharmacist. Fur-
ther research is needed to investigate the quality of the EAI 
training currently offered by GPs and pharmacists.
In this study, the majority of patients classified as prob-
ably food-allergic were not referred for further testing for 
an objective diagnosis of food allergy. It should be noted 
that there is good availability of specialist allergy care for 
pediatric patients in the area where this study was con-
ducted. Infrequent or no referrals of patients to a specialist 
with specific expertise on allergology after an allergic reac-
tion is in agreement with the findings in previous studies [4, 
5]. One might speculate that GPs do not recognize allergic 
reactions or underestimate their severity, and therefore do 
not refer patients for further diagnosis. Implementing clear 
referral criteria could be beneficial to assist GPs to refer 
patients to a specialist with specific expertise on allergology 
when this is needed. In the Northern part of The Nether-
lands our centre and other hospitals can be reached easily 
by car or public transportation. All patients in The Neth-
erlands have health insurance and all costs are covered. In 
our centre we have a waiting list for food challenges. How-
ever, all patients are seen within 2 weeks at the out-patient 
clinic. When necessary they are prescribed an EAI.
In contrast to these results, inappropriate prescription 
or referral of patients who could conceivably be managed 
without an EAI in primary care seems to be numerically 
less of a problem. However, given the impact that over-
estimation of risk may have on patient well being, over-
treatment should be a target for improvement of quality 
of care as well as under-treatment.
Strength of this study is that, to our knowledge, this 
is the first study to assess the epinephrine auto-injector 
prescription practices of general practitioners to food-
allergic patients at high risk for anaphylaxis using data 
recorded by GPs themselves.
A limitation in this study is the number of patients 
excluded from analysis due to inaccessible or incomplete 
patient’s medical records. The incomplete data might 
be due to under-reporting of patients (or their parents), 
under-documentation of clinical information by GPs or 
lack of knowledge and/or practice behavior gaps expe-
rienced by GPs. In this regard, it may be expected there 
would be more food-allergic patients at high risk for ana-
phylaxis not being prescribed an EAI. We did not find 
patients who had been prescribed an EAI who were not 
high risk patients. Ultimately, some of these patients 
would probably show no reactions when challenged with 
the food in question. However, such patients would still 
require an EAI until challenge tests could be done, and 
overestimation of the need for EAIs would thus only be 
apparent after such tests had been completed. Our find-
ings may thus eventually be an overestimation of the 
problem of inadequate EAI prescription to high-risk 
food-allergic patients to some degree. More urgent, how-
ever, is the obvious extent to which high risk food allergic 
patients are not prescribed an EAI by their GPs.
In summary, although previous studies have shown 
that some high risk food-allergic patients do not seek 
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medical care, this study shows with data recorded by GPs 
themselves that those that do visit their GPs are often not 
prescribed an EAI, even to those with a previous severe 
anaphylactic reaction. This shows that previously identi-
fied low rates of EAI ownership may be partly due to GPs 
not prescribing this medication to patients for whom it 
would be  appropriate to do so. These data suggest that 
there is a need for improvement of the quality of care for 
high risk food-allergic patients in primary care.
Conclusions
Food-allergic patients at high risk for anaphylaxis who visit 
their GP are often not prescribed an epinephrine auto-
injector. There is a need for improvement of the quality of 
care for high risk food-allergic patients in primary care.
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